Immunomedics (IMMU) Issues Encouraging Update for Epratuzumab w/ 90Y on …StreetInsider.com (subscription)Immunomedics, Inc. (Nasdaq: IMMU) reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination…
|
Chronische Immun-Thrombozytopenie: Das Ansprechen erhöht sich bei Zugabe …
Deutsches Ärzteblatt Bei der primären Immun-Thrombozytopenie (ITP) werden Thrombozyten durch Vermittlung von Autoantikörpern abgebaut, und gleichzeitig ist ihre Neubildung gestört; klinisch resultieren daraus vor allem Blutungskomplikationen. Kortikosteroide gelten als … |
CTI Announces Data Presentations at the 18th Congress of the European …The Herald | HeraldOnline.comThe SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and …
|
Immunomedics (IMMU) says results from a phase 2 trial suggest adding two …
Seeking Alpha Immunomedics (IMMU) says results from a phase 2 trial suggest adding two doses of epratuzumab may improve elderly large B-cell lymphoma patients’ response to treatment with rituximab and CHOP chemotherapy. CEO Cynthia Sullivan calls the results … |
90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R …GlobeNewswire (press release)… today reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination of rituximab and CHOP chemo…
Global Markets for Orphan Drugs – Focus on BiologicsThe Herald | HeraldOnline.com… Neutroval (Tbo-filgrastim) 59 Gammagard Liquid (Immune Globulin Infusion [Human]) 59 Multiferon (Interferon Alpha) 59 Avonex/Rebif (Interferon Beta-1a) 59 Rituxan/MabT…
|
What’s Hot at EULAR 2013
Medscape “Biosimilars are on the verge of being licensed in Europe, and there will be discussions about infliximab and rituximab — the 2 most prominent ones,” said Dr. Müller-Ladner, from Justus Libig University in Giessen, Germany. The scientific program … |
Elderly patients with CLL benefit from combination therapies vs. chlorambucil …HealioStudy CLL11, presented by Goede and colleagues, examined the efficacy of treatment with GA 101 plus chlorambucil versus rituximab plus chlorambucil versus chlorambuc…
|
Obinutuzumab, rituximab improved chlorambucil efficacy in CLL
Healio CHICAGO — Response rates and survival outcomes with chlorambucil plus obinutuzumab or rituximab were superior to those with chlorambucil alone in a cohort of individuals with chronic lymphocytic leukemia, according to phase 3 study results presented … |
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for …DailyFinancePre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymp…